A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

NCT04523272 Phase 3 ACTIVE_NOT_RECRUITING

This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.

Details

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	Phase 3
Status	ACTIVE_NOT_RECRUITING
Enrolment	528
Start date	2020-08-25
Completion	2025-12

Conditions

• Advanced Renal Cancer

Interventions

• TQB2450
• Anlotinib
• Sunitinib

Primary outcomes

• Progression free survival (PFS) evaluated by Independent Review Committee(IRC) — up to 60 weeks
  PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on IRC.

Countries

China